quisinostat

Small moleculeexperimental

Quisinostat is an experimental drug candidate for the treatment of cancer. It is a "second generation" histone deacetylase inhibitor with antineoplastic activity. It is highly potent against class I and II HDACs. — Wikipedia

Clinical trial activity

6 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2007 (NCT00677105)

Timeline

2000s

Jan 1, 2007
Earliest Phase 1 Sponsor(trial)

2010s

Jan 1, 2011
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cn1cc(CNCC2CCN(c3ncc(C(=O)NO)cn3)CC2)c2ccccc21

Mol. weight: 394.48 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

jnj-2641585
jnj26481585
jnj 26481585
jnj-26481585
jnj-26481585
jnj-26481585
jnj-26481585
quisinostat
quisinostat
quisinostat
quisinostat

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02948075	Phase 2	Sep 1, 2015	Janssen Pharmaceutica NV, NewVac LLC, Russian Academy of Medical Sciences
NCT02728492	Phase 1	Aug 1, 2013	Janssen Pharmaceutica NV, NewVac LLC, Russian Academy of Medical Sciences
NCT01486277	Phase 2	Nov 1, 2011	Johnson and Johnson
NCT01464112	Phase 1	Sep 1, 2011	Johnson and Johnson
NCT00676728	Phase 1	Dec 1, 2008	Johnson and Johnson
NCT00677105	Phase 1	Aug 1, 2007	Janssen Pharmaceutica NV, Johnson and Johnson

Showing 6 of 6 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Johnson and Johnson	For profit	4	4	2	2007
Janssen Pharmaceutica NV	For profit	3	0	2	2007
NewVac LLC	For profit	2	2	2	2013
Russian Academy of Medical Sciences	Academic/Hospital	2	0	2	2013

4 organizations

Page 1 / 1